
NEW ORLEANS -Updated results from two clinical trials of ductal carcinoma in situ (DCIS) continue to support the use of radiation therapy and tamoxifen (Nolvadex) after lumpectomy in these patients. D. Lawrence Wickerham, MD, associate chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP), reported the findings at the American College of Surgeons 87th Clinical Congress.

